AEON Biopharma Inc (AEON): AEON phase-2 trial_in episodic migraine...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

AEON Biopharma Inc (AEON)

Reply Private New

Keep Last Read

Replies (3) Next 10 Prev Next

Send PM Follow Ignore

Followers	829
Posts	119663
Boards Moderated	16
Alias Born	09/05/2002

Re: None

Thursday, 10/19/2023 7:33:45 PM

Thursday, October 19, 2023 7:33:45 PM

AEON phase-2 trial_in episodic migraine misses_ primary_endpoint:

https://finance.yahoo.com/news/aeon-biopharma-announces-topline-results-200500504.html

On the primary endpoint, the topline data showed ABP-450 had a treatment effect with mean reductions in MMD [monthly migraine days] of 4.8 days at the 150U dose (n = 99) and 5.0 days at the 195U dose (n = 108), compared to only 4.2 days in placebo (n = 98) at weeks 21-24, but did not meet statistical significance…

Episodic migraine is (was) ABP-450’s lead indication. The lead indication had previously been cervical dystonia, but AEON backed off from CD due, presumably, to RVNC’s stellar dataset in that indication.

AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau. Please see #msg-172274907 for related info.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Keep Last Read

Replies (3) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent AEON News

Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 08:27:47 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:07:43 PM
Form ARS/A - Annual Report to Security Holders: [Amend] • Edgar (US Regulatory) • 05/14/2024 01:15:36 PM
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/14/2024 01:14:35 PM
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 05/14/2024 01:05:41 PM
Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/23/2023 02:48:14 AM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 02:01:49 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 02:00:14 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/19/2023 08:23:37 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 09:06:34 PM
Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 08/18/2023 09:27:03 PM
Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma • GlobeNewswire Inc. • 08/16/2023 11:00:00 AM
Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 08/12/2023 01:12:00 AM

More AEON News

InvestorsHub NewsWire

Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM

Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM

VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM

ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM

Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM

Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow